tbuckley/cabot-search huggingface dataset:
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
Authors: Homie Razavi, Sarah Robbins, Stefan Zeuzem, Francesco Negro, Maria Buti, Ann-Sofi Duberg, Françoise Roudot-Thoraval, Antonio Craxi, Michael Manns, Rui T Marinho, Bela Hunyady, Massimo Colombo, Soo Aleman, Krasimir Antonov, Perttu Arkkila, Kostas Athanasakis, Sarah Blach, Martin Blachier, Antonio J Blasco, Filipe Calinas, Jose L Calleja, Peer B Christensen, Matthew E Cramp, Esther Croes, Robert J de Knegt, Victor de Ledinghen, Jean-Michel Delile, Chris Estes, Karolin Falconer, Martti Färkkilä, Robert Flisiak, Sona Frankova, Ivane Gamkrelidze, Javier García-Samaniego, Jordan Genov, Jan Gerstoft, Liana Gheorghe, Adrian Goldis, Ilias Gountas, Sergeja Gregorčič, Michael Gschwantler, Jessie Gunter, Waldemar Halota, Laura Harcouet, Christophe Hézode, Patrick Hoffmann, Gabor Horvath, Irena Hrstic, Peter Jarčuška, Deian Jelev, Agita Jeruma, Martin Kåberg, Jennifer Kieran, Loreta A Kondili, Iskren Kotzev, Henrik Krarup, Pavol Kristian, Martin Lagging, Wim Laleman, Pablo Lázaro, Valentina Liakina, Boris Lukšić, Matti Maimets, Mihály Makara, Lyudmila Mateva, Mojca Maticic, Francesco S Mennini, Rumiana Mitova, Christophe Moreno, Joel Mossong, Kimberly Murphy, Helen Nde, Vratislav Nemecek, Dijana Nonkovic, Suzanne Norris, Marian Oltman, Anne L H Øvrehus, George Papatheodoridis, Ken Pasini, Devin Razavi-Shearer, Kathryn Razavi-Shearer, Henk W Reesink, Tatjana Reic, Baiba Rozentale, Stephen D Ryder, Riina Salupere, Rui Sarmento-Castro, Christoph Sarrazin, Jonathan D Schmelzer, Ivan Schréter, Carole Seguin-Devaux, Kaarlo Simojoki, Marietta Simonova, Peter J Smit, Kyriakos Souliotis, Danute Speiciene, Jan Sperl, Peter Stärkel, Daniel Struck, Vana Sypsa, Lelia Thornton, Ieva Tolmane, Krzysztof Tomasiewicz, Jonas Valantinas, Pierre Van Damme, David van de Vijver, Adriaan J van der Meer, Daniela van Santen, Hans Van Vlierberghe, Dominique Vandijck, Stefano Vella, Jerneja Videčnik-Zorman, Wolfgang Vogel, Nina Weis, Angelos Hatzakis
Journal: The Lancet. Gastroenterology & hepatology (2017)
MILD THERAPEUTIC HYPOTHERMIA AND STENT THROMBOSIS: TICAGRELOR BETTER THAN CLOPIDOGREL IN PATIENTS WITH PERCUTANEOUS CORONARY INTERVENTION AFTER CARDIAC ARREST
Authors: Eduardo Flores, Gustavo Jiménez-Brítez, Rodolfo San Antonio, Marco Hernandez, Gala Caixal, John García, Victoria Martin-Yuste, Monica Masotti, Manel Sabaté, Xavier Freixa
Journal: Journal of the American College of Cardiology (2017)
Sensitivity of a Homozygous c-Cbl Mutant AML Cell Line (JPM11) to Tyrosine Kinase Inhibitors, Implications for Potential Targeted Molecular Therapy.
Authors: Hideki Makishima, Yuka Sugimoto, Hadrian Szpurka, Courtney Prince, Michael Clemente, Hideki Muramatsu, Andrew E. Schade, Jaroslaw P. Maciejewski
Journal: Blood (2009)
Mesenchymal Stem Cells in the Treatment of Type 1 DiabetesMellitus
Authors: Jana Katuchova, Denisa Harvanova, Timea Spakova, Rastislav Kalanin, Daniel Farkas, Peter Durny, Jan Rosocha, Jozef Radonak, Daniel Petrovic, Dario Siniscalco, Meirigeng Qi, Miroslav Novák, Peter Kružliak
Journal: Endocrine Pathology (2015)
Amino acid–insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells
Authors: Demetrios Kalaitzidis, Dongjun Lee, Alejo Efeyan, Youmna Kfoury, Naema Nayyar, David B. Sykes, Francois E. Mercier, Ani Papazian, Ninib Baryawno, Gabriel D. Victora, Donna Neuberg, David M. Sabatini, David T. Scadden
Journal: Journal of Clinical Investigation (2017)

The mTOR pathway is a critical determinant of cell persistence and growth wherein mTOR complex 1 (mTORC1) mediates a balance between growth factor stimuli and nutrient availability. Amino acids or glucose facilitates mTORC1 activation by inducing RagA GTPase recruitment of mTORC1 to the lysosomal outer surface, enabling activation of mTOR by the Ras homolog Rheb. Thereby, RagA alters mTORC1-driven growth in times of nutrient abundance or scarcity. Here, we have evaluated differential nutrient-sensing dependence through RagA and mTORC1 in hematopoietic progenitors, which dynamically drive mature cell production, and hematopoietic stem cells (HSC), which provide a quiescent cellular reserve. In nutrient-abundant conditions, RagA-deficient HSC were functionally unimpaired and upregulated mTORC1 via nutrient-insensitive mechanisms. RagA was also dispensable for HSC function under nutritional stress conditions. Similarly, hyperactivation of RagA did not affect HSC function. In contrast, RagA deficiency markedly altered progenitor population function and mature cell output. Therefore, RagA is a molecular mechanism that distinguishes the functional attributes of reactive progenitors from a reserve stem cell pool. The indifference of HSC to nutrient sensing through RagA contributes to their molecular resilience to nutritional stress, a characteristic that is relevant to organismal viability in evolution and in modern HSC transplantation approaches.
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (final report)
Authors: Y. Ohe, S. Negoro, K. Matsui, K. Nakagawa, T. Sugiura, Y. Takada, Y. Nishiwaki, N. Saijo, M. Fukuoka, Y. Ariyoshi
Journal: Journal of Clinical Oncology (2004)

7206
USE OF 18F-FLUORODEOXYGLUCOSE (FDG) POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/CT) FOR DIAGNOSING PROSTHETIC VALVE PERIVALVULAR ABSCESS
Authors: Brittany Weber, Patrycja Galazka, Matthew Steinhauser, Sharmila Dorbala
Journal: Journal of the American College of Cardiology (2017)
PRE-OPERATIVE LONGITUDINAL STRAIN AND STRAIN RATE AS PREDICTORS OF IMPAIRED POST-OPERATIVE EJECTION FRACTION IN PATIENTS OPERATED FOR PURE AORTIC REGURGITATION
Authors: Anne-Julie Boilard, Louis Simard, Lionel Tastet, Nancy Côté, Francois Dagenais, Marie-Annick Clavel
Journal: Journal of the American College of Cardiology (2017)
Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors.
Authors: Stephen R. Rapp, Doug Case, Ann Peiffer, Michelle Joy Naughton, Volker W. Stieber, Gerald K. Bayer, Paul A. Bilodeau, Dennis Frederic Moore, Steven Charles Falchuk, Burton M. Needles, James Piephoff, William j Edenfield, Jeffrey K. Giguere, Nicholette Erickson, Monica Elena Loghin, Edward G. Shaw
Journal: Journal of Clinical Oncology (2013)

2006 Background: This RCT assessed the effect of 24 weeks of 5-10 mg per day of donepezil, an acetyl cholinesterase inhibitor, on cognitive functioning (primary endpoint) and fatigue, mood and QOL in long-term brain tumor survivors following partial or whole-brain irradiation. Cognitive results are reported herein. Methods: From 2/08-12/11,198 adult primary and metastatic brain tumor survivors &gt; 6 months post radiation treatment (&gt;30 Gray) recruited at 24 sites affiliated with the Wake Forest Community Clinical Oncology Program Research Base, 3 CTSU sites and M.D. Anderson Cancer Center were randomly assigned to receive donepezil (n=99) or placebo (n=99). Cognitive function was assessed at baseline, 12 and 24 weeks with Hopkins Verbal Learning Test-Revised, Rey-Osterreith Complex Figure, Trail Making Test, Digit Span, Controlled Oral Word Association, and Grooved Pegboard. A Cognitive Composite (CC) score was the primary outcome. Results: The sample was 91% White, 54% female, and median age was 55 yrs. 66% had primary tumors, 27% brain metastases and 8% PCI. Median time since diagnosis: 38 mos. 95% had 0-1 ECOG performance status scores. 74% completed the study. CC score improved significantly by 24 weeks in both arms (p &lt; .01); however, there was not a statistically significant difference between groups (p = .57). Donepezil group performed better than placebo on HVLT Recognition (p = .03) and Discrimination (p = .01) and GP-Dominant Hand (p = 0.02). Significant interactions were found between treatment arm and baseline cognitive scores for: CC (p = .01), HVLT Immed. Recall (p = .03), HVLT %Savings (p &lt; .01), Digit Span Forward (p = .01), ROCF Copy (p = .03), TMT-B (p = .05) and GP-Dominant (p &lt; .01). In all cases, the benefit of donepezil, relative to placebo, was greater for those with worse baseline scores. Conclusions: Long-term brain tumor survivors treated with brain irradiation who have cognitive impairment can benefit from 5-10mg of donepezil for 24 weeks. Improvements in verbal memory, working memory, visuo- and psychomotor performance and executive functioning were observed in this group. (Study supported by NIH/NINR grant 5R01NR009675-04, NIH/NCI grant 2 U10 CA 81851-09-13 and Eisai, Inc.) Clinical trial information: NCT00369785.
ASSOCIATION BETWEEN CORONARY FLOW RESERVE AND ADVERSE CARDIOVASCULAR EVENTS ALONG A CONTINUUM OF METABOLIC DISEASE IN SYMPTOMATIC PATIENTS WITHOUT OVERT CORONARY ARTERY DISEASE
Authors: Michael Thomas Osborne, Navkaranbir Bajaj, Viviany Taqueti, Paco Bravo, Tomas Vita, Ankur Gupta, Courtney Foster, Meagan Harrington, Victoria Morgan, Jon Hainer, Sharmila Dorbala, Ron Blankstein, Marcelo Di Carli
Journal: Journal of the American College of Cardiology (2017)
G-CSF dosing schedule to prevent eribulin-induced neutropenia: Can modelling and simulation help?
Authors: Antonin Schmitt, Maria Inês Pereira, Isabelle Desmoulins, Nicolas Isambert, Bruno P. Coudert, Pierre Fumoleau
Journal: Journal of Clinical Oncology (2015)

e20673 Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer and should be administered on day 1 and 8 of each 21-day cycle. Neutropenia is one of its major side effects and can lead to delay or interruption of chemotherapy. Non-pegylated granulocyte colony stimulating factor (G-CSF) can be administered in order to prevent or treat chemotherapy-induced neutropenia (CIN). The aim of this study is, based on simulation, to describe the efficacy of G-CSF on CIN and propose an optimal dosing regimen for G-CSF in weekly-treated patients. Methods: Neutrophils time courses in patients treated with eribulin were simulated for 1,000 patients based on van Hasselt model (BJCP 2013) using NONMEM 7. Those data were used to estimate population pharmacokinetic-pharmacodynamic parameters, using Pastor model (Pharm Res 2013). Because Pastor model include exogenous G-CSF effect, it was then possible to run simulations to observe absolute neutrophil count in eribulin-treated patients and to find an appropriate dosing schedule for G-CSF administration. We ran 1,000 simulations for 15 G-CSF dosing schedules and then the number of patients who experienced grade 3 and grade 4 neutropenia was calculated for each dosing schedule and also the duration of neutropenia. Results: G-CSF administration had significant beneficial effects for the majority of the patients but some dosing schedules revealed no overall benefits in preventing or treating chemotherapy-induced neutropenia by comparison with absence of G-CSF. Based on the percentage of patients experiencing grade 3 and 4 neutropenia, the best dosing schedules were selected, but also the worst one. Conclusions: Our study demonstrates that, in weekly chemotherapy such as eribulin, the optimal G-CSF dosing schedule is during 3 days after each administration. We also underlined for the firsttime the potential negative effect of G-CSF. Those results need to be confirmed by a clinical trial, specifically in order to understand the high interindividual variability.
Head and neck squamous cell cancer as part of the germline p16/INK4a mutation-induced FAMMM syndrome
Authors: V. Vinarsky, R. L. Fine, A. Assaad, Y. Qian, J. A. Chabot, G. H. Su, H. Frucht
Journal: Journal of Clinical Oncology (2007)

6052 Background: p16/INK4a constitutes an important cancer susceptibility locus. Germline mutations at this locus have been implicated in several human cancer syndromes, including familial atypical multiple mole melanoma (FAMMM) syndrome, FAMMM-pancreatic cancer (FAMMM-PC) syndrome, and more recently, in familial head and neck cancer syndrome. Methods: We present an individual with a family history of both pancreatic cancer and melanoma, who developed squamous cell carcinoma of the tongue at 21 years old, multiple melanomas, a second squamous cell cancer of the tongue at 40 years old, and ultimately a pancreatic cancer. Results: We identify a germline mutation in INK4a that leads to a substitution of tryptophan for glycine in the Ankyrin III domain of the p16 protein (G101W). We demonstrate loss of heterozygosity at the INK4a locus and lack of p16 expression in the second head and neck squamous cell cancer (HNSCC) tissue. Based on these and on previously published data, we propose that HNSCC resulting from an INK4a germline mutation is a variant of the FAMMM/FAMMM-PC syndrome. Further studies will determine whether there is genotype-phenotype correlation between these syndrome variants. Conclusions: We conclude that young individuals who develop HNSCC should be considered at high-risk for other cancers, including pancreatic cancer and melanoma. They should be advised to avoid cigarette smoking and should be considered for pancreas cancer screening. No significant financial relationships to disclose.
Improving the detection of osteosarcoma tumor margins and metastasis using diagnostic nanoparticles
Authors: A. Dutour, A. Decouveleare, V. Josserand, J. Coll, F. Chotel, R. Rousseau
Journal: Journal of Clinical Oncology (2009)

10512 Background: The aim of osteosarcoma resection is the complete removal of the primary malignant lesion with adequate margins taking into account tumor control and functional reconstruction. To date, no intraoperative method is available to assist surgeons in precisely delineating tumor extension in the adjacent normal tissues. Thus, preoperative imaging and extended surgical resection remains the gold standard. We developed fluorescent nanoparticles RAFT-cRGD 4 -ICG’ targeting αVβ3 integrins on tumor neovessels and demonstrated their capacity to reveal tumor and its margins when exposed to near infrared (NIR) light. Methods: We evaluated in an orthotopic metastatic osteosarcoma in rats the potential of RAFT-cRGD 4 -ICG’ detected intra operatively by NIR illumination to improve margin resection without compromising local tumor control. Controls consisted of pathological margin analysis of the resected tumor/metastasis comparing ICG’ fluorescence with conventional tissue coloration, and pre operative magnetic resonance imaging. Results: We showed a significantly lesser extent of healthy tissue resection after surgical excision when assessing tumor margin intra operatively using RAFT-cRGD 4 -ICG’ and NIR camera compared to preoperative imaging studies and post operative conventional pathology coloration (p&lt;0.01). Importantly, intraoperative NIR illumination of lungs revealed more metastases than by intraoperative manual lung palpation (p&lt;0.01). Conclusions: Our preclinical data confirm the potential of intraoperative imaging for improved primary tumor and lung metastasis excision. We are now generating clinical-grade RAFT-cRGD 4 -ICG’ to further evaluate this approach as a mean to improve functional outcome after surgical excision while maintaining tumor control in patients with relapsed/metastatic osteosarcoma. No significant financial relationships to disclose.
Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies
Authors: Jonathan E. Benjamin, Ginna G. Laport, Laura J. Johnston, Sally Arai, Wen-Kai Weng, Judith A. Shizuru, David B. Miklos, Ruby M. Wong, Linda V. Elder, Karl G. Blume, Robert S. Negrin, Robert Lowsky
Journal: Blood (2008)
NEW-ONSET ATRIAL FIBRILLATION FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: INCIDENCE, ANTICOAGULANT STRATEGY, AND OUTCOMES
Authors: Amit Vora, Dadi (David) Dai, Roland Matsouaka, J. Kevin Harrison, G. Chad Hughes, Matthew Sherwood, Jonathan Piccini, David Cohen, David Holmes, Bhaskar Bhardwaj, Vinod Thourani, Eric Peterson, Sreekanth Vemulapalli
Journal: Journal of the American College of Cardiology (2017)
EXOSOME DERIVED FROM ATRIAL FIBRILLATION PATIENTS PREVENTS PROARRHYTHMIC REMODELING BY RESTORATION OF ACETYLATED TUBULIN IN PACING INDUCED TACHYCARDIA MODEL
Authors: Hyelim Park, Hyoeun Kim, Hyewon Park, Shanyu Cui, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung
Journal: Journal of the American College of Cardiology (2017)
APPROPRIATE USE CRITERIA AND HEALTH STATUS OUTCOMES AFTER CTO PCI: RESULTS FROM THE OPEN CTO REGISTRY
Authors: John Thomas Saxon, Adam Salisbury, James Grantham, James Sapontis, William Lombardi, Dimitrios Karmpaliotis, Jeffrey Moses, Yuanyuan Tang, David Cohen, John Spertus, David Safley
Journal: Journal of the American College of Cardiology (2017)
Ibandronate reduces radiotherapy-resistant metastatic bone pain in patients with solid tumors: A comparison of i.v. and oral formulations
Authors: K. Mystakidou, E. Stathopoulou, E. Parpa, I. Hatzipli, N. Touroutoglou, L. Vlahos
Journal: Journal of Clinical Oncology (2007)

19517 Background: Bisphosphonates are used to treat metastatic bone disease (MBD). However, some bisphosphonates are associated with renal toxicity. Ibandronate (IA) is a single-nitrogen, noncyclic bisphosphonate with a renal safety profile similar to placebo in phase III trials. This study compares the effects of i.v. IA 6mg and oral IA 50mg on bone pain, analgesic intake and renal safety. Methods: Recruited patients fulfilled the following criteria: age ≥18, solid tumors with at least one bone lesion, normal renal (serum creatinine ≤1.5mg/dL) and hepatic function, WHO performance status 0, I or II, life expectancy ≥6 months, normal serum calcium or asymptomatic hypercalcemia. Patients were excluded if they were pregnant or lactating, taking nephrotoxic drugs or osteoclast activity modulators. Eligible patients (n=52) were recruited for a two-arm study, with 26 patients per group treated over 6 months. Groups were matched for age, gender, weight, height, blood pressure, site of primary tumor, site and number of bone metastases and number of irradiated sites. Intravenous IA 6mg was administered over 15 minutes every 4 weeks. Oral IA 50mg was administered as a single, daily tablet before breakfast. Studies were ceased on occurrence of new bone events. Primary endpoint was reduction in bone pain and reduced analgesic use. Results: There were no significant differences in patient demographics between the two treatment arms. The percentage of patients receiving i.v. IA that achieved stable or progressive disease was 15.4%; those receiving oral IA attained 11.5% stable or progressive disease. Pain (Brief Pain Inventory questionnaire) and analgesic intake were assessed at baseline, 3 and 6 months. Both i.v. and oral IA caused a significant and sustainable decrease in each of the pain indices (p&lt;0.0005) with no significant difference between i.v. and oral groups. Both i.v. and oral IA treatment led to a trend in decrease of analgesic use. Conclusions: Oral and i.v. ibandronate have comparable efficacy for palliation of bone pain in MBD patients. No significant financial relationships to disclose.
OUTCOMES OF TRANSCATHETER AND SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH HEPATIC CIRRHOSIS: INSIGHT FROM NATIONWIDE INPATIENT SAMPLE
Authors: Ahmed Almustafa, Vinay Badhwar, Fahad Alqahtani, Sami Aljohani, Ali Hama Amin, Mohammad Akram Kawsara, J. Scott Rankin, Lawrence Wei, Mohamad Alkhouli
Journal: Journal of the American College of Cardiology (2017)
Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells Reduces the Time to Platelet Engraftment and the Number of Platelet and Red Blood Cell Transfusions Required in Patients Receiving Myleloblative Cord Blood Transplants
Authors: Emily R Cox, Qian Vicky Wu, Rachel Salit, Colleen Delaney, Filippo Milano
Journal: Blood (2016)
Locally Advanced Colon Cancer: Evaluation of Current Clinical Practice and Treatment Outcomes at the Population Level
Authors: Charlotte E.L. Klaver, Lieke Gietelink, Willem A. Bemelman, Michel W.J.M. Wouters, Theo Wiggers, Rob A.E.M. Tollenaar, Pieter J. Tanis
Journal: Journal of the National Comprehensive Cancer Network (2017)

Background: The goal of this study was to evaluate current clinical practice and treatment outcomes regarding locally advanced colon cancer (LACC) at the population level. Methods: Data were used from the Dutch Surgical Colorectal Audit from 2009 to 2014. A total of 34,527 patients underwent resection for non-LACC and 6,918 for LACC, which was defined as cT4 and/or pT4 stage. LACC was divided into those with multivisceral resection (LACC-MV; n=3,385) and without (LACC-noMV; n=1,595). Guideline adherence, treatment strategy, and short-term outcomes were evaluated. Results: Guideline adherence was >90% regarding preoperative imaging and ≥80% regarding preoperative multidisciplinary team (MDT) discussion. In the elective setting, neoadjuvant chemoradiotherapy (chemoRT) was applied in 6.2% of the cT4 cases, and neoadjuvant chemotherapy in 4.0%. R0 resection rates were 99%, 91%, and 87% in patients with non-LACC, LACC-noMV, and LACC-MV, respectively (P<.001). A postoperative complicated course occurred in 17%, 25%, and 29% of patients (P<.001), and the 30-day/in-hospital mortality rate was 3.6%, 6.0%, and 5.4% (P<.001) in the non-LACC, LACC-noMV, and LACC-MV groups, respectively. Discussion/Conclusions: This population-based study suggests that there is room for improvement in the treatment of LACC, with regard to short-term surgical outcomes and oncologic outcomes (ie, radicality of resection). Improvement might be expected from optimized preoperative imaging, routine MDT discussions, and further specialization and centralization of care. Optimized use of neoadjuvant treatment strategies based on already available and upcoming evidence is likely to result in a better margin status and thereby a better long-term prognosis. Furthermore, lower R0 resection rates in an emergency setting suggest a potential role for bridging strategies in order to enable optimal staging, neoadjuvant treatment, and elective surgery by a surgical team most optimally qualified for the procedure.
Angiogenic Factors in Chronic Myelogenous Leukemia: Evaluation at Diagnosis and After 3 and 6 Months of Treatment with Imatinib.
Authors: Leonardo Carvalho Palma, Nadiele Fatima de Marco Fagundes, Fabiano Pinto Saggioro, Fernando Chahud, Luciana Correa Oliveira de Oliveira, Barbara Amelia Aparecida Santana-Lemos, Eduardo Magalhaes Rego, Thiago Vilarinho Tavares, Maria Helena Silva Scaffo, Ana Maria Anselmi Dorigan, Suleimy Cristina Mazin, Aglair B Garcia, Belinda Pinto Simoes
Journal: Blood (2009)
IL-15 Augments in-Vitro Expansion and Functional Activity of Antigen-Specific Effector Memory T-Cells (TEM) While Co-Expression of IL-15 and IL-15 Rα on Antigen Presenting Cells Also Promotes Expansion of Central Memory T-Cells (TCM)
Authors: Aisha Hasan, Annamalai Selvakumar, Bo Dupont, Michel Sadelain, Isabelle Riviere, Richard J O’Reilly
Journal: Blood (2008)